Dr. Grace K. Dy, MD

Dr. Dy practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Dy's NPI, 1639143795, was assigned on February 15, 2006. Dr. Dy holds New York license 002956.

Dr. Dy's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Dy's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Dy is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Dr. Dy to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dy practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dy's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dy is licensed in New York.

CMS data shows 229 Medicare services from Dr. Dy across 4 procedure codes in 2024, for 85 Medicare patients. Medicare paid $19,164 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 85 Medicare patients who saw Dr. Dy in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have cancer, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dy's median patient age at 72, with 57% women.

In 2024, Dr. Dy wrote 193 Medicare Part D claims for 74 patients. 72% of them were for generic drugs. CMS names the drug for 103 of them, across 5 drugs with 11 or more claims each, at $497,873 in total drug cost. In 2023, CMS named 84 claims across 5 drugs.

Dr. Dy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 95 papers to Dr. Dy, published from 2011 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Dy has published most often in J Thorac Oncol. Dr. Dy's most frequent co-authors are Marc Stuart Ernstoff, MD, Wen Wee Ma, MD and Chukwumere E. Nwogu, MD.

Dmand AI links Dr. Dy to 11 clinical trials, 3 of them phase 1/2 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Medullary. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Dy that name 1 trial.

CMS Open Payments shows 151 general payments to Dr. Dy from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. AstraZeneca Pharmaceuticals LP paid the most, $32,911. It also lists 8 research payments totaling $3,641 from 2021 to 2025, naming 1 clinical trial.